<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01013909</url>
  </required_header>
  <id_info>
    <org_study_id>13957</org_study_id>
    <secondary_id>2008-005654-21</secondary_id>
    <nct_id>NCT01013909</nct_id>
  </id_info>
  <brief_title>Comparative Safety and Efficacy Study of New Bifonazol Spray vs Terbinafine Solution vs Placebo</brief_title>
  <acronym>Porsche</acronym>
  <official_title>An Investigator-blind, Randomized, Multicenter, 5-arm, Placebo- and Active Controlled Parallel Group Pilot Trial to Explore the Efficacy and Tolerability of Topical Bifonazole Liquid Spray in Patients With Athlete's Foot.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study shall prove whether 6 consecutive doses of Bifonazole spray show comparable
      efficacy to a Terbinafine solution applied once.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of erythema, scaling, vesiculation maceration, and pruritus based on a categorial scale (0=absent to 3 =severe), assessment of mycological cure based on cultures and microscopy</measure>
    <time_frame>After 6 applications (7 and 42 days after start of treatment)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Local side effects on the skin</measure>
    <time_frame>From day 1 through day 42</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical cure</measure>
    <time_frame>After 6 applications (7 and 42 days after start of treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mycological cure</measure>
    <time_frame>After 6 applications (7 and 42 days after start of treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of negative culture</measure>
    <time_frame>After 6 applications (7 and 42 days after start of treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of microscopy negative</measure>
    <time_frame>After 6 applications (7 and 42 days after start of treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of absence of itching and burning</measure>
    <time_frame>After 6 applications (7 and 42 days after start of treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of Adverse Event</measure>
    <time_frame>From visit 2 (day 3) till visit 7 (day 42)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Signs</measure>
    <time_frame>Visit 1 (day 1) and visit 7 (day 42)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local side effects</measure>
    <time_frame>From visit 2 (day 3) till visit 7 (day 42)</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">220</enrollment>
  <condition>Tinea Pedis</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 5</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bifonazole spray once daily</intervention_name>
    <description>Application of one dose daily by means of an metered dose</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bifonazole spray twice daily</intervention_name>
    <description>Application of two dose daily by means of an metered dose</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Application of one dose daily by means of an metered dose</description>
    <arm_group_label>Arm 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Application of one dose daily by means of an metered dose</description>
    <arm_group_label>Arm 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamisil Once</intervention_name>
    <description>One application of Lamisil Once</description>
    <arm_group_label>Arm 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects aged between 18 and 70 years

          -  Positive clinical findings of athlete's foot, limited to interdigital spaces, with a
             total athlete's foot severity score (AFSS) of at least 5 and not exceeding 10 points
             for the signs and symptoms of athlete's foot, and no sign or symptom scoring 'severe'

        Exclusion Criteria:

          -  Clinical history suggestive of intolerance or allergies to one of the products or the
             ingredients of the products

          -  Plantar tinea pedis (&quot;Mocassin-type&quot;)

          -  Onychomycosis of any toe

          -  Previous treatment with a systemic antifungal within 6 months prior to screening

          -  Previous treatment of feet with a topical antifungal within 4 weeks prior to screening

          -  Previous treatment with a topical antifungal applied to other areas of the body than
             feet within 2 weeks prior to screening

          -  Previous treatment of any topical medication applied to the feet within 2 weeks prior
             to screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>10437</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>13055</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>13187</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>13439</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <link>
    <url>http://www.bayerpharma.com/en/research-and-development/clinical-trials/trial-finder/index.php</url>
    <description>Click here to find results for studies related to Bayer Healthcare products.</description>
  </link>
  <link>
    <url>http://www.clinicaltrialsregister.eu</url>
    <description>Click here and search for websynopsis provided by the EMA</description>
  </link>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 9, 2009</study_first_submitted>
  <study_first_submitted_qc>November 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2009</study_first_posted>
  <last_update_submitted>January 26, 2015</last_update_submitted>
  <last_update_submitted_qc>January 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bifonazole</keyword>
  <keyword>Terbinafine</keyword>
  <keyword>Reduced treatment duration</keyword>
  <keyword>Efficacy</keyword>
  <keyword>Safety</keyword>
  <keyword>Athlete's foot</keyword>
  <keyword>Moderate severity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tinea Pedis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Terbinafine</mesh_term>
    <mesh_term>Bifonazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

